CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.72
−2.35%Year over year
Reported trailing growth
- Revenue
- -50.0%
- EBITDA
- -5.2%
- EBIT
- -5.4%
- EPS
- +37.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +88.0%
Three-year CAGR
- Revenue
- -59.2%
- EBITDA
- -11.8%
- EBIT
- -6.9%
- Net income
- -9.1%
- EPS
- +32.1%
- Free cash flow
- -10.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026